Ticker brief
TNGX TANGO THERAPEUTICS INC
Consumer, Non-cyclical · Biotechnology
last close
$23.34
1 day
-7.7%
14 days
-8.8%
mkt cap
$4.8B
signals 14d
21
authors 14d
6
crowd 14d
+0.4σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 85% | IV/HV 1.29× (as of 2026-07-22) |
| Skew — 25Δ RR 30d | -0.024 | 25Δ call IV − put IV |
| Net dealer OI (NDOI) | +0.20 elevated | 5-session Δ n/a (as of 2026-06-26) |
| OI alarm | quiet | last alarm 2026-06-09 (z=2.4) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-27 · now -0.15 (−1 bearish … +1 bullish)
Who spoke6
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | -0.45 | 9 | +0.41 |
| @semodough | C | -3.01 | 4 | +0.43 |
| @Pharmdca | C | +0.82 | 4 | +0.72 |
| @OptionsFlowBoss | C | · | 2 | +0.33 |
| @Quantumup1 | C | · | 1 | +0.40 |
| @Biomaven | A | +1.79 | 1 | +0.30 |
Recent signals21of 21 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-27 | @bioinvestor24 | -0.15 | Questions extreme therapy pricing while comparing costs and revenue burdens across several drug makers. | -7.7% | tweet ↗ |
| 2026-08-26 | @bioinvestor24 | +0.75 | Says TNGX and ERAS have several-fold upside versus RVMD and discourages chasing RVMD. | -8.4% | tweet ↗ |
| 2026-08-26 | @bioinvestor24 | +0.20 | Questions insurance access for RVMD at a $500K price and discusses future comparative trials by TNGX and ERAS. | -8.4% | tweet ↗ |
| 2026-08-26 | @bioinvestor24 | +0.55 | Names TNGX and ERAS as preferable cancer-company opportunities. | -8.4% | tweet ↗ |
| 2026-08-26 | @bioinvestor24 | +0.55 | Highlights a seven-million-share TNGX transfer while deriding institutions committed to RVMD. | -8.4% | tweet ↗ |
| 2026-08-26 | @bioinvestor24 | +0.35 | Suggests recent institutional share support and upcoming GBM data could matter for TNGX. | -8.4% | tweet ↗ |
| 2026-08-26 | @bioinvestor24 | +0.75 | Argues TNGX-ERAS combinations could reduce long-run use of RVMD's drug due to potency and liver-enzyme issues. | -8.4% | tweet ↗ |
| 2026-08-26 | @semodough | +0.20 | Reports 43 million shares short in Tango despite enthusiasm for Tango and Revolution Medicines. | -8.4% | tweet ↗ |
| 2026-08-26 | @Biomaven | +0.30 | Views RASONQUE as a broad oncology opportunity with future lung, CRC, and combination development. | -8.4% | tweet ↗ |
| 2026-08-26 | @OptionsFlowBoss | +0.30 | Lists six stocks with unusual bullish options-volume multiples during the session. | -8.4% | tweet ↗ |
| 2026-08-26 | @semodough | +0.70 | Calls their combination highly active and highlights a roughly 12-month first-mover advantage plus Phase 3 plans. | -8.4% | tweet ↗ |
| 2026-08-26 | @Pharmdca | +0.65 | Presents and owns a three-company pancreatic-cancer treatment basket. | -8.4% | tweet ↗ |
| 2026-08-26 | @Pharmdca | +0.70 | Explicitly discloses long positions in all three stocks. | -8.4% | tweet ↗ |
| 2026-08-25 | @bioinvestor24 | +0.45 | Argues AMGN should consolidate oncology assets and identifies TNGX and ERAS as best fits. | -5.8% | tweet ↗ |
| 2026-08-21 | @OptionsFlowBoss | +0.35 | Reports a $430K call buyer, indicating bullish options flow. | -2.3% | tweet ↗ |
| 2026-08-19 | @Pharmdca | +0.72 | Buy selective biotech names on post-data dips. — Cites positive pancreatic-cancer data and explicitly recommends buying dips after data. | -7.4% | tweet ↗ |
| 2026-08-17 | @semodough | +0.40 | Cites a favorable Stifel note with a $40 target and three year-end catalysts | -7.7% | tweet ↗ |
| 2026-08-17 | @Pharmdca | +0.80 | Discloses ownership and a bullish combination-therapy thesis supported by 92% response data. | -7.7% | tweet ↗ |
| 2026-08-17 | @bioinvestor24 | +0.25 | Reviews resistance-mechanism research and suggests ERAS and TNGX approaches may improve durability, pending clinical data. | -7.7% | tweet ↗ |
| 2026-08-17 | @Quantumup1 | +0.40 | Stifel reiterated Buy on TNGX with a $40 target and discussed upcoming ESMO data. | -7.7% | tweet ↗ |
| 2026-08-17 | @semodough | +0.40 | Stifel sets a $40 target and relays constructive management takeaways ahead of ESMO data. | -7.7% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.